Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum Sells 128,127 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 128,127 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the sale, the chief executive officer now directly owns 97,687 shares in the company, valued at $5,692,221.49. This trade represents a 56.74 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Andrew Dudum also recently made the following trade(s):

• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.22, for a total value of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.08, for a total transaction of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.
• On Thursday, January 16th, Andrew Dudum sold 36,460 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total transaction of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.38, for a total value of $1,118,663.94.

Hims & Hers Health Stock Down 3.6 %

Shares of NYSE HIMS traded down $2.46 during trading on Thursday, reaching $66.28. 30,711,275 shares of the stock were exchanged, compared to its average volume of 15,817,041. The business’s 50-day moving average price is $33.94 and its 200 day moving average price is $25.19. The company has a market capitalization of $14.48 billion, a price-to-earnings ratio of 150.64 and a beta of 1.35. Hims & Hers Health, Inc. has a twelve month low of $9.22 and a twelve month high of $72.98.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently bought and sold shares of the company. Crewe Advisors LLC acquired a new position in Hims & Hers Health in the fourth quarter worth $28,000. Raleigh Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. lifted its position in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health in the 4th quarter worth about $38,000. 63.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HIMS. Deutsche Bank Aktiengesellschaft raised their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Bank of America boosted their price objective on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a report on Thursday. Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Finally, Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price objective for the stock from $42.00 to $60.00 in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.53.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.